瑞康医药(002589) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥2,018,758,765.18, a decrease of 2.62% compared to ¥2,073,027,669.16 in the same period last year[5] - Net profit attributable to shareholders decreased by 28.31% to ¥15,168,972.69 from ¥21,159,565.23 year-on-year[5] - The net profit after deducting non-recurring gains and losses increased significantly by 526.70% to ¥18,162,174.56, compared to a loss of ¥4,256,424.09 in the previous year[5] - Net profit for Q1 2024 was CNY 18,571,098.80, a decline of 38.2% compared to CNY 29,983,448.04 in Q1 2023[24] - The net profit attributable to shareholders of the parent company was CNY 15,168,972.69, down 28.4% from CNY 21,159,565.23 in the previous year[24] - Basic and diluted earnings per share for Q1 2024 were both CNY 0.010, compared to CNY 0.014 in Q1 2023[24] Cash Flow - The net cash flow from operating activities was negative at -¥54,084,542.82, a decline of 171.55% from ¥75,590,663.40 in the same period last year[5] - Cash received from operating activities decreased by 55.70% to ¥8,108.61 from ¥18,304.63 in the same period last year[13] - The net cash flow from operating activities for Q1 2024 was -54,084,542.82, compared to a positive net cash flow of 75,590,663.40 in Q1 2023, indicating a significant decline[27] - Cash paid for operating activities totaled 2,231,248,746.34, compared to 2,352,780,522.41 in the previous year, indicating a decrease of approximately 5%[27] - The cash received from the disposal of subsidiaries and other business units was 81,419,056.38, down from 334,580,526.88 in Q1 2023, marking a decline of about 76%[27] Assets and Liabilities - Total assets at the end of the reporting period were ¥15,558,939,780.85, down 6.88% from ¥16,709,306,031.48 at the end of the previous year[5] - The company’s total liabilities increased, with notes payable rising by 235.93% to ¥150,696.14 from ¥44,859.88 year-on-year[10] - Total liabilities decreased to CNY 9,903,391,687.96 from CNY 11,072,329,037.39 year-over-year[23] - The total number of common shareholders at the end of the reporting period is 83,325[15] - The largest shareholder, Zhang Renhua, holds 13.39% of shares, totaling 201,498,159 shares, with 90,874,100 shares pledged[15] Investment and Expenses - Investment income dropped by 90.61% to ¥500.35 from ¥5,328.83 year-on-year due to the divestiture of subsidiaries[11] - The company reported a 53.21% decrease in financial expenses to ¥5,565.88 from ¥11,894.68 in the previous year[11] - Research and development expenses for Q1 2024 were CNY 3,103,612.68, an increase from CNY 2,846,655.14 in the same period last year[23] - The company reported a financial expense of CNY 55,658,801.00, significantly reduced from CNY 118,946,779.26 in Q1 2023[23] Inventory and Receivables - Accounts receivable increased from 3,762,988,324.45 RMB to 3,950,732,855.74 RMB, reflecting a growth of approximately 5%[19] - Inventory decreased from 1,119,070,006.89 RMB to 978,041,450.83 RMB, a decline of about 12.6%[19] Cash and Equivalents - The company's cash and cash equivalents decreased from 5,060,786,524.48 RMB to 4,022,756,394.67 RMB[18] - The total cash inflow from financing activities was 5,942,289,521.45, while cash outflow was 5,831,685,791.87, resulting in a net inflow of 110,603,729.58[27] - The total cash and cash equivalents increased by 130,806,158.63 during the quarter, compared to an increase of 381,285,003.94 in Q1 2023[27]